Ironwood Pharmaceuticals Inc (IRWD) — 8-K Filings

8-K Filings (25)

• 8-K Filing — May 7, 2026
• Ironwood Pharmaceuticals Enters Material Definitive Agreement — Dec 23, 2025 Risk: medium
  On December 18, 2025, Ironwood Pharmaceuticals, Inc. entered into a material definitive agreement. The filing also indicates other events and includes financial
• 8-K Filing — Nov 26, 2025
• Ironwood Pharma Announces Executive & Director Changes — Oct 10, 2025 Risk: medium
  Ironwood Pharmaceuticals, Inc. announced on October 7, 2025, changes in its executive and director roles. The filing details the departure of certain officers a
• Ironwood Pharmaceuticals to be Acquired for $1 Billion — Sep 3, 2025 Risk: medium
  Ironwood Pharmaceuticals, Inc. announced on August 29, 2025, that it has entered into a definitive agreement to be acquired by Astrea Acquisition LLC. The trans
• Ironwood Pharmaceuticals Files 8-K on Financials — Aug 7, 2025 Risk: low
  On August 7, 2025, Ironwood Pharmaceuticals, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial sta
• Ironwood Pharmaceuticals Changes Certifying Accountant — Jul 10, 2025 Risk: low
  Ironwood Pharmaceuticals, Inc. filed an 8-K on July 10, 2025, reporting a change in its certifying accountant as of July 3, 2025. The company, headquartered in
• Ironwood Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 12, 2025 Risk: low
  Ironwood Pharmaceuticals, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders as of June 10, 2025. The filing detai
• Ironwood Pharmaceuticals Faces Delisting Notice — Jun 3, 2025 Risk: high
  Ironwood Pharmaceuticals, Inc. filed an 8-K on May 28, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, incorp
• Ironwood Pharmaceuticals Files 8-K on Operations — May 7, 2025 Risk: low
  Ironwood Pharmaceuticals, Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition, and filing financial statements and
• Ironwood Pharmaceuticals Files 8-K on Financials — Apr 25, 2025 Risk: low
  On April 25, 2025, Ironwood Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition
• Ironwood Pharmaceuticals Files 8-K Report — Apr 14, 2025 Risk: low
  On April 14, 2025, Ironwood Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific materia
• Ironwood Pharma Faces Delisting Notice — Mar 27, 2025 Risk: high
  Ironwood Pharmaceuticals, Inc. filed an 8-K on March 27, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a
• Ironwood Pharmaceuticals Files 8-K on Operations — Feb 27, 2025 Risk: low
  Ironwood Pharmaceuticals, Inc. filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition. The filing also includes finan
• Ironwood Pharma Discloses Exit Costs & Officer Changes — Jan 29, 2025 Risk: medium
  Ironwood Pharmaceuticals, Inc. reported on January 17, 2025, regarding costs associated with exit or disposal activities, and also disclosed the departure of di
• Ironwood Pharma Appoints New CFO, Adds Directors — Dec 5, 2024 Risk: medium
  Ironwood Pharmaceuticals, Inc. announced on December 2, 2024, changes in its executive and director roles. The company elected two new directors, Dr. Lisa A. De
• Ironwood Pharma Elects New Directors, Adjusts CMO Compensation — Nov 12, 2024 Risk: low
  Ironwood Pharmaceuticals, Inc. announced on November 6, 2024, changes in its board of directors and executive compensation. Specifically, the company elected tw
• Ironwood Pharmaceuticals Files 8-K on Financials — Nov 7, 2024 Risk: low
  Ironwood Pharmaceuticals, Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition. The filing includes financial s
• Ironwood Pharmaceuticals Enters Material Agreement, Creates Financial Obligation — Sep 30, 2024 Risk: medium
  On September 27, 2024, Ironwood Pharmaceuticals, Inc. entered into a material definitive agreement, likely related to financing or a significant business transa
• Ironwood Pharmaceuticals Files 8-K on Financials — Aug 8, 2024 Risk: low
  On August 8, 2024, Ironwood Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements a
• Ironwood Pharmaceuticals Files 8-K on Shareholder Votes — Jun 21, 2024 Risk: low
  Ironwood Pharmaceuticals, Inc. filed an 8-K on June 21, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain spec
• Ironwood Pharmaceuticals Appoints New CFO — Jun 20, 2024 Risk: low
  Ironwood Pharmaceuticals, Inc. announced on June 20, 2024, the appointment of Michael L. Smith as Chief Financial Officer, effective July 1, 2024. Smith previou
• Ironwood Pharmaceuticals Files 8-K on Financials — May 9, 2024 Risk: low
  Ironwood Pharmaceuticals, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Ironwood Pharma Files 8-K on Q4 Results & Financial Condition — Feb 15, 2024 Risk: low
  IRONWOOD PHARMACEUTICALS, INC. filed an 8-K on February 15, 2024, reporting on "Results of Operations and Financial Condition" and "Financial Statements and Exh
• IRWD Files 8-K for M&A/Tender Offer Related Communications — Jan 8, 2024
  IRONWOOD PHARMACEUTICALS, INC. filed an 8-K on January 8, 2024, indicating that it is making a filing intended to simultaneously satisfy obligations under Rule

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX